Corcept Therapeutics Incorporated, a company focused on developing medications for severe endocrine, oncological, metabolic, and neurological disorders, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). This application is for their selective cortisol modulator, relacorilant, as a treatment for patients with platinum-resistant ovarian cancer. This marks a significant milestone for Corcept, as it now has two NDAs under FDA review. The submission is backed by positive results from Phase 3 ROSELLA and Phase 2 trials, showing improved patient outcomes without increasing the safety burden. The company is preparing for potential regulatory approval to offer better treatment options for patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.